510(k) device
pRESET LITE Thrombectomy Device
Phenox Limited · Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL, Class II) · First FDA decision Oct 21, 2023, newest Oct 21, 2023Acute ischemic stroke
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "pRESET LITE"
MAUDE reports
0
Brand "pRESET LITE", since 2015
PubMed studies
3
Mentioning "pRESET LITE"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing pRESET LITE Thrombectomy Device
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K231539 · Decided Oct 21, 2023 · 144 days after receipt
Device type: Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "pRESET LITE", any status and sponsor, newest update first.
No registered device study names "pRESET LITE".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "pRESET LITE", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code POL
97 reports: 40 malfunction, 55 injury, 2 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "pRESET LITE"[tiab]. The summary above synthesizes these.
- Use of the pRESET LITE thrombectomy device in combined approach for medium vessel occlusions: A multicenter evaluation.
Wang M, Henkes H, Ghozy S, et al. · Neuroradiology · 2024Review
- Flow diversion in challenging vascular anatomies: the use of low profile stent retrievers for safe and accurate positioning of the microcatheter.
Quäschling U, Kläver M, Richter C, et al. · CVIR Endovasc · 2020
- Stent Retriever Thrombectomy of Small Caliber Intracranial Vessels Using pREset LITE: Safety and Efficacy.
Kurre W, Aguilar-Pérez M, Martinez-Moreno R, et al. · Clin Neuroradiol · 2017
Other devices of this type
Also filed under product code POL.
- Trevo NXT ProVue RetrieverStryker Neurovascular · 510(k) 2023
- Trevo NXT ProVue RetrieverStryker · 510(k) 2020
- Solitaire 2 Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 510(k) 2019
- pRESET Delta Thrombectomy Device and pRESET Delta LITE Thrombectomy DevicePhenox Limited · 510(k) 2025
- pRESET Thrombectomy DevicePhenox Limited · 510(k) 2023
- Solitaire X Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 510(k) 2021
- Trevo XP ProVue Retriever and Trevo NXT ProVue RetrieverStryker Neurovascular · 510(k) 2020
- Solitaire Platinum Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 510(k) 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.